Terazosin: intravenous safety evaluation in rats.
Terazosin, an alpha-adrenergic antagonist, was administered as a 15 mg/ml solution to rats intravenously at a rate of 2 ml/min. Under these conditions the LD50 was 277 mg/kg for males and 293 mg/kg for females. When administered daily for 1 month at dosages of 0, 10, 40 or 150 mg/kg/day, the no-toxic-effect dosage was 40 mg/kg/day. Evidence of toxicity at 150 mg/kg included hypothermia and deaths. Death resulted from acute, exaggerated pharmacologic effects leading to cardiorespiratory failure. Evidence of sympatholytic activity observed at lower dosages included hypoactivity, blepharoptosis, ptyalism and splenic congestion.
D000818:Animals; D000959:Antihypertensive Agents / Q000633:toxicity*; D001763:Blepharoptosis / Q000139:chemically induced; D001831:Body Temperature / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects; D005260:Female; D007275:Injections, Intravenous; D008099:Liver / Q000187:drug effects; D008297:Male; D010879:Piperazines / Q000633:toxicity*; D011224:Prazosin / Q000031:analogs & derivatives*; D051381:Rats; D011919:Rats, Inbred Strains
D000959:Antihypertensive Agents; D010879:Piperazines; C041226:Terazosin; D011224:Prazosin